Premium Reports
High-Volume Unit Dose Packaging 2008

High-Volume Unit Dose Packaging 2008

| Read Time: Unknown

On February 25, 2004, the Food and Drug Administration (FDA) issued a landmark release that outlined the rules governing barcode requirements for human drugs and blood. The new rule requires certain human drug and biological product labels to have barcodes. This rule applies to manufacturers, repackers, relabelers, and private label distributers of prescription drug products and over-the-counter drugs. However, while the barcode requirement is mandatory for packaged shipments from the manufacturer, it is not mandatory at the unit dose level.

Given that barcode labels are not required for unit doses of drugs, what solutions are available to ensure the integrity of the medication administration process from the shipments with barcode labels to unit dose medications? Is there an ROI for the organizations that adopt a high-volume unit dose packaging system? What successes and challenges have healthcare providers reported in adopting unit dose packaging products? Do these systems positively impact patient care?

KLAS interviewed 138 healthcare provider professionals regarding the experiences they are having with their unit dose packaging system and vendor to find out answers to these and other questions.

Products qualifying for ranking in the study were:

  • AmerisourceBergen Technology Group (ABTG) FastPak EXP
  • McKesson PACMED
  • Talyst AutoPack

Early findings were also included for Omnicell WorkflowRx Packager and Swisslog PillPick

Want to see full details?

 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2018 KLAS Enterprises, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.